 Bradley Corr
Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 9 | 2023 | 141 | 3.160 |
Why?
| | Ovarian Neoplasms | 7 | 2022 | 386 | 1.950 |
Why?
| | Carcinoma, Endometrioid | 3 | 2022 | 46 | 1.920 |
Why?
| | beta Catenin | 4 | 2023 | 218 | 1.430 |
Why?
| | Lymph Nodes | 2 | 2018 | 415 | 0.950 |
Why?
| | Wnt Signaling Pathway | 2 | 2021 | 146 | 0.820 |
Why?
| | Uterine Cervical Neoplasms | 5 | 2023 | 213 | 0.720 |
Why?
| | Wnt Proteins | 1 | 2021 | 134 | 0.690 |
Why?
| | Mutation | 5 | 2023 | 3338 | 0.670 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2018 | 61 | 0.560 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 44 | 0.540 |
Why?
| | Venous Thromboembolism | 2 | 2020 | 230 | 0.530 |
Why?
| | Cisplatin | 2 | 2023 | 262 | 0.510 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2015 | 34 | 0.500 |
Why?
| | Keratin-5 | 1 | 2015 | 46 | 0.490 |
Why?
| | Tumor Suppressor Protein p53 | 4 | 2023 | 445 | 0.490 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 850 | 0.480 |
Why?
| | Hysterectomy | 4 | 2019 | 105 | 0.470 |
Why?
| | Antineoplastic Agents | 4 | 2023 | 1875 | 0.450 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 1356 | 0.440 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 48 | 0.440 |
Why?
| | Cholangiocarcinoma | 1 | 2013 | 38 | 0.430 |
Why?
| | Bile Duct Neoplasms | 1 | 2013 | 56 | 0.430 |
Why?
| | Genital Neoplasms, Female | 3 | 2024 | 70 | 0.390 |
Why?
| | Lymph Node Excision | 3 | 2018 | 140 | 0.380 |
Why?
| | Neoplasm Grading | 3 | 2022 | 241 | 0.360 |
Why?
| | Biomarkers, Tumor | 4 | 2023 | 1032 | 0.350 |
Why?
| | Female | 27 | 2024 | 59324 | 0.330 |
Why?
| | Middle Aged | 17 | 2023 | 26605 | 0.280 |
Why?
| | Aged, 80 and over | 11 | 2023 | 6306 | 0.260 |
Why?
| | Immunohistochemistry | 2 | 2023 | 1624 | 0.260 |
Why?
| | Cell Survival | 2 | 2021 | 1014 | 0.250 |
Why?
| | Humans | 29 | 2024 | 114045 | 0.240 |
Why?
| | Cell Line, Tumor | 3 | 2021 | 2700 | 0.220 |
Why?
| | Neoplasms | 3 | 2022 | 2086 | 0.220 |
Why?
| | Bevacizumab | 2 | 2022 | 114 | 0.220 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 31 | 0.220 |
Why?
| | DNA Polymerase II | 2 | 2023 | 37 | 0.220 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 126 | 0.210 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2022 | 14 | 0.200 |
Why?
| | Aged | 13 | 2023 | 18969 | 0.200 |
Why?
| | Camptothecin | 1 | 2022 | 96 | 0.190 |
Why?
| | Thrombocytopenia | 1 | 2023 | 177 | 0.190 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2021 | 28 | 0.190 |
Why?
| | Retrospective Studies | 6 | 2022 | 12521 | 0.190 |
Why?
| | Indazoles | 1 | 2021 | 57 | 0.180 |
Why?
| | Neoplasm Staging | 3 | 2019 | 1162 | 0.180 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 437 | 0.180 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 45 | 0.170 |
Why?
| | Benzoxazoles | 1 | 2020 | 16 | 0.170 |
Why?
| | Imidazoles | 1 | 2021 | 203 | 0.170 |
Why?
| | Azepines | 1 | 2020 | 69 | 0.170 |
Why?
| | Mindfulness | 1 | 2021 | 98 | 0.170 |
Why?
| | Enoxaparin | 1 | 2020 | 52 | 0.170 |
Why?
| | Disease Susceptibility | 1 | 2021 | 316 | 0.160 |
Why?
| | Pyridones | 1 | 2020 | 122 | 0.160 |
Why?
| | Microsatellite Instability | 1 | 2019 | 32 | 0.160 |
Why?
| | Survival Analysis | 3 | 2020 | 1206 | 0.160 |
Why?
| | Margins of Excision | 1 | 2019 | 29 | 0.160 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2020 | 636 | 0.160 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1145 | 0.160 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 76 | 0.160 |
Why?
| | Cross-Sectional Studies | 3 | 2018 | 4402 | 0.160 |
Why?
| | Adult | 12 | 2023 | 30375 | 0.160 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 347 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 2 | 2023 | 784 | 0.150 |
Why?
| | Recurrence | 1 | 2021 | 925 | 0.150 |
Why?
| | Oncologists | 1 | 2018 | 30 | 0.150 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 140 | 0.150 |
Why?
| | Frozen Sections | 1 | 2018 | 24 | 0.150 |
Why?
| | Pyridines | 1 | 2021 | 419 | 0.150 |
Why?
| | Preoperative Care | 2 | 2017 | 319 | 0.150 |
Why?
| | Disease Management | 1 | 2021 | 556 | 0.140 |
Why?
| | Pyrimidines | 1 | 2020 | 374 | 0.140 |
Why?
| | Pyrazoles | 1 | 2020 | 361 | 0.140 |
Why?
| | Minority Groups | 1 | 2018 | 223 | 0.140 |
Why?
| | Amyotrophic Lateral Sclerosis | 3 | 2003 | 60 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 660 | 0.130 |
Why?
| | Anticoagulants | 1 | 2020 | 547 | 0.130 |
Why?
| | Gynecology | 1 | 2018 | 163 | 0.130 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 48 | 0.130 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 438 | 0.120 |
Why?
| | Perioperative Period | 1 | 2015 | 47 | 0.120 |
Why?
| | Radiography, Thoracic | 1 | 2016 | 150 | 0.120 |
Why?
| | Surgeons | 1 | 2018 | 236 | 0.120 |
Why?
| | Laparotomy | 1 | 2015 | 101 | 0.120 |
Why?
| | Treatment Outcome | 3 | 2020 | 9049 | 0.120 |
Why?
| | Heparin | 1 | 2015 | 225 | 0.110 |
Why?
| | Quality of Health Care | 1 | 2018 | 572 | 0.110 |
Why?
| | Robotic Surgical Procedures | 1 | 2015 | 86 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2019 | 1016 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 371 | 0.100 |
Why?
| | Postoperative Complications | 2 | 2020 | 2122 | 0.100 |
Why?
| | Breast Neoplasms | 1 | 2024 | 1846 | 0.100 |
Why?
| | Prognosis | 5 | 2023 | 3315 | 0.100 |
Why?
| | Combined Modality Therapy | 2 | 2013 | 1117 | 0.100 |
Why?
| | Ovary | 1 | 2013 | 190 | 0.100 |
Why?
| | Case-Control Studies | 1 | 2019 | 3003 | 0.100 |
Why?
| | Prospective Studies | 4 | 2023 | 6195 | 0.090 |
Why?
| | Maximum Tolerated Dose | 2 | 2022 | 183 | 0.090 |
Why?
| | Cohort Studies | 2 | 2023 | 4883 | 0.090 |
Why?
| | Immunotherapy | 1 | 2012 | 473 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2015 | 2173 | 0.080 |
Why?
| | Apoptosis | 1 | 2015 | 2349 | 0.070 |
Why?
| | Young Adult | 4 | 2021 | 10444 | 0.060 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 4 | 0.060 |
Why?
| | Wnt4 Protein | 1 | 2024 | 17 | 0.060 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 37 | 0.050 |
Why?
| | Registries | 3 | 2018 | 1764 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2159 | 0.050 |
Why?
| | Mesylates | 1 | 2022 | 7 | 0.050 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2022 | 15 | 0.050 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 170 | 0.050 |
Why?
| | Platinum | 1 | 2022 | 38 | 0.050 |
Why?
| | Ligands | 1 | 2024 | 556 | 0.050 |
Why?
| | Adolescent | 4 | 2021 | 17800 | 0.050 |
Why?
| | Antibodies, Bispecific | 1 | 2022 | 32 | 0.050 |
Why?
| | Ambulatory Care Facilities | 1 | 2003 | 212 | 0.050 |
Why?
| | Paclitaxel | 1 | 2022 | 190 | 0.050 |
Why?
| | Decision Trees | 1 | 2000 | 82 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2020 | 51 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 55 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 97 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2022 | 496 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 428 | 0.040 |
Why?
| | Patient Care Team | 1 | 2003 | 517 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 521 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 695 | 0.040 |
Why?
| | Ireland | 3 | 2003 | 24 | 0.040 |
Why?
| | Program Evaluation | 1 | 2021 | 820 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2018 | 187 | 0.040 |
Why?
| | Disease Progression | 2 | 2020 | 2371 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2018 | 305 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 945 | 0.030 |
Why?
| | RNA | 1 | 2022 | 806 | 0.030 |
Why?
| | Ileus | 1 | 2015 | 10 | 0.030 |
Why?
| | Salpingectomy | 1 | 2015 | 13 | 0.030 |
Why?
| | Caregivers | 1 | 2021 | 713 | 0.030 |
Why?
| | Urinary Retention | 1 | 2015 | 19 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1638 | 0.030 |
Why?
| | Ovariectomy | 1 | 2015 | 116 | 0.030 |
Why?
| | Blood Loss, Surgical | 1 | 2015 | 82 | 0.030 |
Why?
| | Pelvis | 1 | 2015 | 89 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2018 | 632 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1310 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 1829 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4392 | 0.030 |
Why?
| | Patient Readmission | 1 | 2018 | 607 | 0.030 |
Why?
| | United States | 2 | 2019 | 12137 | 0.030 |
Why?
| | Signal Transduction | 1 | 2024 | 4501 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 2012 | 184 | 0.020 |
Why?
| | Length of Stay | 1 | 2015 | 957 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1175 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 2343 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 770 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 2885 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2003 | 1331 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1257 | 0.020 |
Why?
| | Mice | 1 | 2020 | 14843 | 0.010 |
Why?
| | Male | 4 | 2020 | 55396 | 0.010 |
Why?
| | Interprofessional Relations | 1 | 2003 | 246 | 0.010 |
Why?
| | Central Nervous System Diseases | 1 | 2000 | 60 | 0.010 |
Why?
| | Animals | 1 | 2020 | 31565 | 0.010 |
Why?
| | Age of Onset | 1 | 2000 | 444 | 0.010 |
Why?
| | Palliative Care | 1 | 2003 | 641 | 0.010 |
Why?
|
|
Corr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|